Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Watson gets US and Canadian rights to Antares' Anturol

Executive Summary

Watson Pharmaceuticals Inc. (urology and women’s health products) has licensed exclusive US and Canadian rights to Antares Pharma Inc.’s (self-injection and gel therapeutics) Anturol topical oxybutynin gel for overactive bladder (OAB). The FDA is reviewing the NDA and set a December 8, 2011 PDUFA date.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing

Related Companies